Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice - PubMed (original) (raw)
Comparative Study
. 2005 Mar 3;45(5):675-88.
doi: 10.1016/j.neuron.2005.01.040.
Affiliations
- PMID: 15748844
- DOI: 10.1016/j.neuron.2005.01.040
Free article
Comparative Study
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice
Lauren M Billings et al. Neuron. 2005.
Free article
Abstract
Progressive memory loss and cognitive dysfunction are the hallmark clinical features of Alzheimer's disease (AD). Identifying the molecular triggers for the onset of AD-related cognitive decline presently requires the use of suitable animal models, such as the 3xTg-AD mice, which develop both amyloid and tangle pathology. Here, we characterize the onset of learning and memory deficits in this model. We report that 2-month-old, prepathologic mice are cognitively unimpaired. The earliest cognitive impairment manifests at 4 months as a deficit in long-term retention and correlates with the accumulation of intraneuronal Abeta in the hippocampus and amygdala. Plaque or tangle pathology is not apparent at this age, suggesting that they contribute to cognitive dysfunction at later time points. Clearance of the intraneuronal Abeta pathology by immunotherapy rescues the early cognitive deficits on a hippocampal-dependent task. Reemergence of the Abeta pathology again leads to cognitive deficits. This study strongly implicates intraneuronal Abeta in the onset of cognitive dysfunction.
Comment in
- Homing in on intracellular Abeta?
Golde TE, Janus C. Golde TE, et al. Neuron. 2005 Mar 3;45(5):639-42. doi: 10.1016/j.neuron.2005.02.013. Neuron. 2005. PMID: 15748837 Review.
Similar articles
- Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid.
Giménez-Llort L, Blázquez G, Cañete T, Johansson B, Oddo S, Tobeña A, LaFerla FM, Fernández-Teruel A. Giménez-Llort L, et al. Neurosci Biobehav Rev. 2007;31(1):125-47. doi: 10.1016/j.neubiorev.2006.07.007. Epub 2006 Oct 20. Neurosci Biobehav Rev. 2007. PMID: 17055579 Review. - Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z. Zhang W, et al. Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14. Behav Brain Res. 2011. PMID: 21513747 - Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Trinchese F, et al. Ann Neurol. 2004 Jun;55(6):801-14. doi: 10.1002/ana.20101. Ann Neurol. 2004. PMID: 15174014 - Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease.
Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW. Olcese JM, et al. J Pineal Res. 2009 Aug;47(1):82-96. doi: 10.1111/j.1600-079X.2009.00692.x. Epub 2009 Jun 17. J Pineal Res. 2009. PMID: 19538338 - Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.
Gouras GK, Almeida CG, Takahashi RH. Gouras GK, et al. Neurobiol Aging. 2005 Oct;26(9):1235-44. doi: 10.1016/j.neurobiolaging.2005.05.022. Neurobiol Aging. 2005. PMID: 16023263 Review.
Cited by
- Enhanced expression of glia maturation factor correlates with glial activation in the brain of triple transgenic Alzheimer's disease mice.
Zaheer S, Thangavel R, Wu Y, Khan MM, Kempuraj D, Zaheer A. Zaheer S, et al. Neurochem Res. 2013 Jan;38(1):218-25. doi: 10.1007/s11064-012-0913-z. Epub 2012 Oct 20. Neurochem Res. 2013. PMID: 23086473 Free PMC article. - Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin.
Zenaro E, Pietronigro E, Della Bianca V, Piacentino G, Marongiu L, Budui S, Turano E, Rossi B, Angiari S, Dusi S, Montresor A, Carlucci T, Nanì S, Tosadori G, Calciano L, Catalucci D, Berton G, Bonetti B, Constantin G. Zenaro E, et al. Nat Med. 2015 Aug;21(8):880-6. doi: 10.1038/nm.3913. Epub 2015 Jul 27. Nat Med. 2015. PMID: 26214837 - Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.
Declercq LD, Vandenberghe R, Van Laere K, Verbruggen A, Bormans G. Declercq LD, et al. Front Pharmacol. 2016 Mar 31;7:88. doi: 10.3389/fphar.2016.00088. eCollection 2016. Front Pharmacol. 2016. PMID: 27065872 Free PMC article. Review. - Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons.
Rajmohan R, Reddy PH. Rajmohan R, et al. J Alzheimers Dis. 2017;57(4):975-999. doi: 10.3233/JAD-160612. J Alzheimers Dis. 2017. PMID: 27567878 Free PMC article. Review. - Ubisol-Q10, a Nanomicellar and Water-Dispersible Formulation of Coenzyme-Q10 as a Potential Treatment for Alzheimer's and Parkinson's Disease.
Wear D, Vegh C, Sandhu JK, Sikorska M, Cohen J, Pandey S. Wear D, et al. Antioxidants (Basel). 2021 May 11;10(5):764. doi: 10.3390/antiox10050764. Antioxidants (Basel). 2021. PMID: 34064983 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases